Phase II/III Outsourcing Partner Selection Attributes
In the beginning of 2022, ISR surveyed 132 sponsors worldwide who outsource Phase II/III studies and asked them to identify attributes that are important to them when selecting an outsourcing partner. The research revealed that respondents valued operational excellence and therapeutic expertise highly when choosing a provider for their Phase II/III studies.
Desired Integrated Clinical Activities
In Q1 2022, ISR surveyed 100 sponsors who outsource clinical logistics and asked them which activities they would like to source from a single service provider for a trial. Learn why clinical labeling, clinical supply chain management, and storage and distribution of clinical trial materials received the most votes.
Top 5 improvements Needed In Today’s EDC Software Systems
EDC systems allow a variety of users to input, review, and present the data obtained throughout a clinical trial. In 2020, 130 respondents responsible for outsourcing EDC were asked how they would improve today’s EDC software systems. See the results in the available infographic.
How To Improve eCOA/ePRO Software Systems
eCOA/ePRO systems are necessary tools to properly capture, review, and present data collected throughout clinical trial. 118 respondents involved in clinical trials expressed their thoughts regarding what improvements needed to be made to eCOA/ePRO software systems. Find out the top improvements they thought were necessary.
Why Phase II/III Service Providers Lose Bids
In Q2, 2020, ISR asked 146 respondents involved in outsourcing Phase II/III services what is the main reason a CRO may lose bids for Phase II/III work. High cost topped the list, capturing 37% of respondents’ votes. Followed by Lack of therapeutic experience (19%) and Lack of understanding of the trial outcomes (12%).
Patient Recruitment Challenges In Rare Disease Studies
In Q2, 2020, ISR asked 125 respondents involved in patient recruitment and retention activities for rare disease studies about challenges they face while recruiting patients. The data below show the most challenging issue reported by respondents in finding patients for their recent rare disease studies was Multiple sites with access to only a few patients (42%). Followed by Multiple entities pursuing same small pool of patients (19%) and Rigid inclusion/exclusion criteria leading to high screenout rate (15%).
Central IRB Outsourcing Practices By Company Size
In Q3, 2019, ISR asked outsourcers of Central IRB services about how uniform the use of Central IRBs is within their organization. In terms of company size, respondents from small companies report that their company uses the same Central IRB on All or most of the studies at a higher rate than those from large companies (45% vs 38%). Mid-size companies were similar to large companies, with 37% of respondents reporting their company used the same Central IRB for all studies.
Most Important Selection Criteria For Central IRB Services
In Q3, 2019, ISR asked 111 respondents responsible for the selection of Central IRB services about the most important attributes when choosing a Central IRB. Not surprisingly, communication and timeliness are highly valued. Clearly communicates expectations for submissions, Defines time-frames for review and reporting, Is fully AAHRPP accredited, Provides excellent customer service, and Offers fast turnaround time are the most important attributes with more than half of respondents considering them moderately or very important when selecting a Central IRB.
3 Year Rolling Average – Phase I Service Provider Customer Loyalty
In Q4, 2019, ISR asked sponsors who outsource phase I trials to better understand customer loyalty. CRO loyalty is computed as an index that consists of likelihood to recommend, likelihood to use again, and overall satisfaction. The data below show companies with twenty or more user ratings over the past 3 years and an industry average derived from all CROs included in the research.
Most Important Capabilities For Pharmacovigilance Services
In Q4, 2019, ISR asked outsourcers of drug safety / pharmacovigilance services about the most important capabilities when choosing a pharmacovigilance provider. Regulatory compliance tops the list as the most important capability for service provider selection. Half of respondents picked it among their top five capabilities and 15% of respondents selected it as the most important capability.